Vimarsana
Biggest News Aggregation in the World

Page 2 - Anticancer Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anticancer Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anticancer Research Today - Breaking & Trending Today

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer - Vimarsana News

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Application based on results from the TROPION-Lung01 Phase III trial If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed antibody drug conjugate...

Opioid Use for Pain Persists After Treatment for Many With Cervical Cancer - Vimarsana News

Opioid Use for Pain Persists After Treatment for Many With Cervical Cancer

Nearly 40% of patients who received treatment for cervical cancer were still being prescribed outpatient opioids for pain management six months later, according to recently published study findings.

Cannabinoids (Marijuana Compounds) Kill Leukemia Cancer Cells - Vimarsana News

Cannabinoids (Marijuana Compounds) Kill Leukemia Cancer Cells

Yes, marijuana can fight cancer. One new study reveals how various compounds within cannabis are able to work together to kill human leukemia cells.

Best Whey Protein Powders 2023: Top 5 Brand Reviews - Vimarsana News

Best Whey Protein Powders 2023: Top 5 Brand Reviews

If you're looking for the best whey protein powders for 2023, here are five options to consider. Find out more about whey protein here.

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial - Vimarsana News

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--